Recombinant VEGFA anticorps

N° du produit ABIN7490571

L’anticorps anti-VEGFA Chimeric Human est utilisé pour la détection de VEGFA dans des échantillons de Humain. Il a été validé pour FACS.

Aperçu rapide pour Recombinant VEGFA anticorps (ABIN7490571)

Antigène: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Type d'anticorp: Recombinant Antibody

Fragment: Fc fragment

Reactivité: Humain

Hôte: Human, Lapin

Clonalité: Chimeric

Conjugué: Cet anticorp VEGFA est non-conjugé

Application: Flow Cytometry (FACS)

Clone: DMC276

Détail du produit anti-VEGFA anticorps

Fonction: Anti-VEGFA antibody(DMC276), IgG1 Chimeric mAb

Purification: Purified from cell culture supernatant by affinity chromatography

Isotype: IgG1

Information d'application

Indications d'application: Flow Cyt 1:100

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Please see Certificate of Analysis for specific instructions of reconstitution.

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Stock: -20 °C,-80 °C

Stockage commentaire: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Date de péremption: 12 months

Détails sur VEGFA

Antigène: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Autre désignation: VEGFA

Sujet: MVCD1, VEGF, VPF,
Description: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

UniProt: P15692

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Regulation of Cell Size, Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling